In this video: The Controversial 84% Cancer Study | Nicolas Hulscher ✅Valasta Astaxanthin : https://valasta.net/ (Checkout with code POI5 for 5% discount) ✅BBACK Shoes: https://bbackworld.us (Get 10% off your order with code POI10) ✅HAVN: havnwear.com (The world's first EMF-blocking clothing) Discount code: POI15 for 15% off Please register your patients at - www.tremorstudy.com ✅StemRegen: http://www.stemregen.co/drstephen (Special Offer: Save 15% Using Code "SBPOD" At Checkout) ✅Nature's Marvels : https://profound-health.com/product-category/bioregulators/?aff=PODOF (A Trusted Source for Natural & Synthetic Bioregulators)

Season 9 starts with one of the most controversial and data-heavy conversations we've released yet.

This week on Pod of Inquiry, we sit down with epidemiologist Nicolas Hulscher, MPH of the McCullough Foundation to discuss a newly published prospective observational study involving 200 cancer patients prescribed off-label ivermectin and mebendazole through a telemedicine platform.

The headline finding: 84.4% of patients reported clinical benefit at six months — including 32% with no evidence of disease.

In this episode, we explore: 🧬 The surprising biological overlap between parasites and cancer cells 📊 What the real-world data actually showed across 20+ cancer types 💨 Why ivermectin once had one of the strongest safety reputations in medicine 💰 The financial realities surrounding off-patent therapies ⚠️ Rising concerns around aggressive cancers and excess mortality trends 📝 How peer review, publishing, and medical gatekeeping shape what reaches the public 🔬 Upcoming McCullough Foundation research on mortality data, VAERS trends, and more

Whether you're a clinician, patient, caregiver, or simply trying to make sense of the rapidly changing cancer landscape, this conversation dives into the claims, the controversies, and the data driving the debate.

Follow Pod of Inquiry 📘 Facebook: https://www.facebook.com/podofinquiry 📸 Instagram: https://www.instagram.com/podofinquiry 🐦 X (Twitter): https://www.x.com/podofinquiry 🔗 LinkedIn (Dr. Stephen Barrett): https://www.linkedin.com/in/stephen-barrett-92776a51/

Visit our website https://podofinquiry.com/latest-episodes/ - click on the show link to read the show notes and get more information.

Timestamps: 00:00 Intro 01:24 Nicolas Hulscher's Background 02:50 Parasites & Cancer Pathways 04:23 Ivermectin's Safety History 06:22 Study Design Explained 07:30 Cancer Patient Cohort 09:00 84.4% Clinical Benefit 10:50 Dosing & Side Effects 14:20 Chemotherapy Concerns 15:00 Sponsor — ValAsta 17:00 Chemo, Radiation & Biopsies 19:48 Study Censorship Claims 22:00 Why Off-Patent Drugs Aren't Studied 24:30 Trial Ethics Debate 26:30 The 'Journal Cartel' 30:00 Sponsor — BBACK 0524 31:30 What Real Science Should Look Like 34:26 Origins of 'Turbo Cancer' Research 36:00 Cancer in Younger Patients 38:42 The Rise of 'Turbo Cancer' 41:03 What's Next for McCullough Foundation 43:04 Where to Find Nicolas Hulscher 44:53 Sponsor — STEMRegen 47:03 Closing Remarks

-- Hashtags -- #CancerResearch #Ivermectin #Mebendazole #PodOfInquiry #NicolasHulscher #McCulloughFoundation #Oncology #MedicalResearch #HealthPodcast #CancerCare